Crossmark

From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson’s disease. A systematic review and meta-analysis of placebo-controlled trials

Crossref DOI link: https://doi.org/10.1007/s10072-025-08411-4

Published Online: 2025-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Badran, Ahmed Samy https://orcid.org/0009-0002-8445-778X
Gbreel, Mohamed Ibrahim
License Information

Text and Data Mining valid from 2025-08-21

Version of Record valid from 2025-08-21
More Information

Article History

Received: 23 June 2025

Accepted: 29 July 2025

First Online: 21 August 2025

Declarations

:

: This meta-analysis was based on previously published studies, and ethical approval was not required.

: Not applicable.

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below